Middle East & Africa Parkinson’s Disease Treatment Market Research Report – Segmented By Drug Class, Distribution Channel, Patient Care Setting & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)
The size of the MEA Parkinson’s Disease Treatment Market was worth USD 0.46 billion in 2022 and estimated to be growing at a CAGR of 4.807%, to reach USD 0.58 billion by 2027.
Parkinson's disease is primarily symptomatic, with no curative therapeutic options available. The primary goal of Parkinson's disease treatment is to keep signs and symptoms, including shakiness in the hands, trouble walking, and slowness of movement under control. Each person's treatment strategy is unique to their symptoms.
The treatment market for Parkinson's disease is expected to grow due to increasing environmental variables and genetic inheritance in the MEA region. In addition, recent advancements in Parkinson's disease treatment, such as combination therapies to extend the action of continuous dopaminergic stimulation drugs, approval for Neurostimulation devices, neuroprotective therapies to slow disease prognosis, gene therapy, neural transplantation, and others, are expected to drive massive growth in the MEA Parkinson's disease treatment market over the forecast period.
Y-O-Y rise in the aging population, which is expected to be aided by the rising prevalence of Parkinson's disease and anticipated to accelerate the market's growth rate during the forecast period in this region. Increasing research and development investment results in creating novel treatments, which is expected to help the market expand. The demand for Parkinson's disease treatment will increase as people become more aware of viable treatments.
In addition, factors such as increasing advances in the creation of innovative pharmaceuticals and expanding health infrastructure in numerous MEA countries are expected to fuel market expansion in the future years. Furthermore, rising healthcare spending, driven by consumer demand for high-quality services, is likely to increase market expansion.
Parkinson's disease is a neurodegenerative disease that predominantly affects the human brain, making it difficult to function and carry out daily tasks. Parkinson's disease is characterized by a lack of dopamine production, which results in stiffness, tremors, and difficulty walking, among other symptoms. If not treated promptly, this condition can become quite serious. However, due to the pandemic's resource constraints and diversion, effective symptomatic therapy for Parkinson's disease is no longer available.
This research report on the Middle East & Africa Parkinson’s disease treatment market has been segmented and sub-segmented into the following categories:
By Drug Class:
- Dopamine Receptor Antagonists
- Pramipexole
- Ropinirole
- Apomorphine
- Rotigotine
- Mono Amine Oxidase Inhibitors
- Selegiline
- Rasagiline
- Carbidopa
- Anticholinergics
- Other Drug Classes
By Distribution Channels:
- Retailer Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Patient Care Setting:
- Clinics
- Hospitals
By Country:
- KSA
- UAE
- Israel
- Rest of GCC countries
- South Africa
- Ethiopia
- Kenya
- Egypt
- Sudan
- Rest of MEA
Geographically, the Middle East and Africa regional markets are forecasted to account for a moderate share of the global market during the forecast period. The growing burden of Parkinson's disease management on large countries' healthcare systems, such as the UAE and Kuwait, would encourage the government to make concerted efforts to accelerate R&D in Parkinson's disease therapy.
KEY MARKET PLAYERS:
Companies playing an influential role in the MEA Parkinson’s Disease Treatment Market profiled in the report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.1 Dopamine Receptor Antagonists
5.1.1.1 Pramipexole
5.1.1.2 Ropinirole
5.1.1.3 Apomorphine
5.1.1.4 Rotigotine
5.1.2 Mono Amine Oxidase Inhibitors
5.1.2.1 Selegiline
5.1.2.2 Rasagiline
5.1.3 Carbidopa
5.1.4 Anticholinergics
5.1.5 Other Drug Classes
5.1.6 Y-o-Y Growth Analysis, By Drug Class
5.1.7 Market Attractiveness Analysis, By Drug Class
5.1.8 Market Share Analysis, By Drug Class
5.2 Distribution Channel
5.2.1 Retailer Pharmacies
5.2.2 Hospital Pharmacies
5.2.3 Online Pharmacies
5.2.4 Y-o-Y Growth Analysis, By Distribution Channel
5.2.5 Market Attractiveness Analysis, By Distribution Channel
5.2.6 Market Share Analysis, By Distribution Channel
5.3 Patient Care Setting
5.3.1 Clinics
5.3.2 Hospitals
5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting
5.3.4 Market Attractiveness Analysis, By Patient Care Setting
5.3.5 Market Share Analysis, By Patient Care Setting
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Drug Class
6.1.3.2 By Distribution Channel
6.1.3.3 By Patient Care Setting
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Drug Class
6.1.4.2 By Distribution Channel
6.1.4.3 By Patient Care Setting
6.1.5 Market Share Analysis
6.1.5.1 By Drug Class
6.1.5.2 By Distribution Channel
6.1.5.3 By Patient Care Setting
6.2 Middle-East
6.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Teva
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 GSK
8.4 AbbVie
8.5 Merck
8.6 Boehringer Ingelheim
8.7 Impax Laboratories
8.8 Lundbeck
8.9 Sun Pharma
8.10 Wockhardt
8.11 UCB
8.12 Valeant Pharmaceuticals
8.13 Acadia
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
- Middle East and Africa Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
Middle East and Africa Dopamine Receptor Antagonists Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Mono Amine Oxidase Inhibitors Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Carbidopa Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Anticholinergics Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Other Drug Classes Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
Middle East and Africa Retailer Pharmacies Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Hospital Pharmacies Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Online Pharmacies Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
Middle East and Africa Clinics Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East and Africa Hospitals Market, By Region, From 2022 - 2027 ( USD Billion )
Middle East Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
Middle East Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
Middle East Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
Africa Parkinson’s Disease Treatment Market, By Drug Class , From 2022 - 2027 ( USD Billion )
Africa Parkinson’s Disease Treatment Market, By Distribution Channel , From 2022 - 2027 ( USD Billion )
Africa Parkinson’s Disease Treatment Market, By Patient Care Setting, From 2022 - 2027 ( USD Billion )
Related Reports
ASK FOR CUSTOMIZATION
Talk to our analyst and get customised report done according to your research needs
INQUIRE FOR DISCOUNT
Check if you can avail any discount. Submit your details and our team will get back to you.
DOWNLOAD FREE SAMPLE
Request to avail a free sample report that reflects this market and its growth.
